Helicobacter pylori gyrA conferring resistance to fluoroquinolones

Accession ARO:3007052
CARD Short NameHpyl_gyrA_FLO
DefinitionPoint mutations in the quinolone resistance-determining regions of Helicobacter pylori observed to confer resistance to fluoroquinolone antibiotics.
AMR Gene Familyfluoroquinolone resistant gyrA
Drug Classfluoroquinolone antibiotic
Resistance Mechanismantibiotic target alteration
Resistomes with Sequence VariantsHelicobacter pylorig+wgs
Classification11 ontology terms | Show
Parent Term(s)2 ontology terms | Show
+ confers_resistance_to_antibiotic levofloxacin [Antibiotic]
+ fluoroquinolone resistant gyrA [AMR Gene Family]
Publications

Lee JW, et al. 2011. Helicobacter 16(4):301-10 Mutations of Helicobacter pylori associated with fluoroquinolone resistance in Korea. (PMID 21762270)

Chang WL, et al. 2012. Helicobacter 17(3):210-5 Gemifloxacin can partially overcome quinolone resistance of H. pylori with gyrA mutation in Taiwan. (PMID 22515359)

Garcia M, et al. 2012. Antimicrob Agents Chemother 56(1):550-1 Distribution of spontaneous gyrA mutations in 97 fluoroquinolone-resistant Helicobacter pylori isolates collected in France. (PMID 22064536)

Phan TN, et al. 2015. Int J Antimicrob Agents 45(3):244-8 High rate of levofloxacin resistance in a background of clarithromycin- and metronidazole-resistant Helicobacter pylori in Vietnam. (PMID 25499186)

Miftahussurur M, et al. 2016. BMC Microbiol 16(1):256 Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal. (PMID 27809767)

Hanafi A, et al. 2016. Front Microbiol 7:2015 Molecular and Proteomic Analysis of Levofloxacin and Metronidazole Resistant Helicobacter pylori. (PMID 28018334)

Miftahussurur M, et al. 2016. PLoS One 11(12):e0166199 Surveillance of Helicobacter pylori Antibiotic Susceptibility in Indonesia: Different Resistance Types among Regions and with Novel Genetic Mutations. (PMID 27906990)

Rhie SY, et al. 2020. Antibiotics (Basel) 9(6): Discovery of a Novel Mutation in DNA Gyrase and Changes in the Fluoroquinolone Resistance of Helicobacter pylori over a 14-Year Period: A Single Center Study in Korea. (PMID 32471292)

Wei W, et al. 2023. Front Cell Infect Microbiol 13:1294379 Antibiotic resistance of Helicobacter pylori in Nanjing, China: a cross-section study from 2018 to 2023. (PMID 38089809)

Miftahussurur M, et al. 2019. Infect Drug Resist 12:345-358 Alternative eradication regimens for Helicobacter pylori infection in Indonesian regions with high metronidazole and levofloxacin resistance. (PMID 30774400)

Teh X, et al. 2014. PLoS One 9(7):e101481 Functional and molecular surveillance of Helicobacter pylori antibiotic resistance in Kuala Lumpur. (PMID 25003707)

Resistomes

Prevalence of Helicobacter pylori gyrA conferring resistance to fluoroquinolones among the sequenced genomes, plasmids, and whole-genome shotgun assemblies available at NCBI or IslandViewer for 413 important pathogens (see methodological details and complete list of analyzed pathogens). Values reflect percentage of genomes, plasmids, genome islands, or whole-genome shotgun assemblies that have at least one hit to the AMR detection model. Default view includes percentages calculated based on Perfect plus Strict RGI hits. Select the checkbox to view percentages based on only Perfect matches to AMR reference sequences curated in CARD (note: this excludes resistance via mutation as references in protein variant models are often wild-type, sensitive sequences).

Prevalence: protein variant model (view sequences)

SpeciesNCBI ChromosomeNCBI PlasmidNCBI WGSNCBI GI
Helicobacter pylori16.41%0%18.84%0%
Show Perfect Only


Detection Models

Model Type: protein variant model

Model Definition: Protein Variant Models (PVM) perform a similar search as Protein Homolog Models (PHM), i.e. detect protein sequences based on their similarity to a curated reference sequence, but secondarily screen query sequences for curated sets of mutations to differentiate them from antibiotic susceptible wild-type alleles. PVMs are designed to detect AMR acquired via mutation of house-keeping genes or antibiotic targets, e.g. a mutated gyrase resistant to aminocoumarin antibiotics. PVMs include a protein reference sequence (often from antibiotic susceptible wild-type alleles), a curated bit-score cut-off, and mapped resistance variants. Mapped resistance variants may include any or all of single point mutations, insertions, or deletions curated from the scientific literature. A Strict RGI match has a BLASTP bit-score above the curated BLASTP cutoff value and contains at least one curated mutation from amongst the mapped resistance variants, while a Loose RGI match has a bit-score less than the curated BLASTP bit-score cut-off but still contains at least one curated mutation from amongst the mapped resistance variants.

Bit-score Cut-off (blastP): 1400

Legend:

  • discovered in clinical, agricultural, or environmental isolates

  • discovered via laboratory selection experiments

  • ReSeqTB https://platform.reseqtb.org

Published Variants:

PMID: 21762270N87K N87I N87Y D91G D91N D91Y D91Y,A97V
PMID: 22515359N87K,H57Y D91N,A97V D91N,V77A
PMID: 22064536T87I A88P D91H
PMID: 25499186N87A,A88N,V65I
PMID: 27809767S63P,D91N S63P,N87K,P188S S63P,R130K N87K,D91N,V172I D91N,R130K D99V
PMID: 28018334V172I
PMID: 27906990R140K,D192N D34N D34Y,R140K D91G,D161N
PMID: 32471292G85C
PMID: 38089809D87G
PMID: 3077440045612,A129T+45613,S479G 45612,D91N+45613,R484K 45612,D91N,A129T+45613,S479G 45612,N87Y+45613,R484K
PMID: 2500370745612,D91G,V199I+45613,D481E 45612,D91N+45613,D481E,D484K 45612,D91N,V199I+45613,D481E,D484K 45612,N87K+45613,F438S 45612,N87K,V199A+45613,D481E,R484K 45612,N87K,V199I+45613,D484K

>gb|WP_001153763.1|+|Helicobacter pylori gyrA conferring resistance to fluoroquinolones [Helicobacter pylori]
MQDNSVNETKNIVEVGIDSSIEESYLAYSMSVIIGRALPDARDGLKPVHRRILYAMHELG
LTSKVAYKKSARIVGDVIGKYHPHGDNAVYDALVRMAQDFSMRLELVDGQGNFGSIDGDN
AAAMRYTEARMTKASEEILRDIDKDTIDFVPNYDDTLKEPDILPSRLPNLLVNGANGIAV
GMATSIPPHRMDEIIDALVHVLENPNAGLDEILEFVKGPDFPTGGIIYGKAGIIEAYKTG
RGRVKVRAKVHVEKTKNKEIIVLDEMPFQTNKAKLVEQISDLAREKQIEGISEVRDESDR
EGIRVVIELKRDAMSEIVLNHLYKLTTMETTFSIILLAIYNKEPKIFTLLELLHLFLNHR
KTIIIRRTIFELEKAKARAHILEGYLIALDNIDEIVRLIKTSQSPEAAKNALMERFTLSE
IQSKAILEMRLQRLTGLERDKIKEEYQNLLELIDDLNGILKSEDRLNGVVKTELLEVKEQ
FSSPRRTEIQESYENIDIEDLIANEPMVVSMSYKGYVKRVDLKAYEKQNRGGKGKLSGST
YEDDFIENFFVANTHDILLFITNKGQLYHLKVYKIPEASRIAMGKAIVNLISLAPDEKIM
ATLSTKDFSDERSLAFFTKNGVVKRTNLSEFESNRSCGIRAIVLDEGDELVSAKVVDKNA
KHLLIASHLGIFIKFPLEEVREIGRTTRGVIGIKLNENDFVVGAVVISDDGNKLLSVSEN
GLGKQTLAEAYRGQSRGGKGVIGMKLTQKTGNLVGVISVDDENLDLMILTASAKMIRVSI
KDIRETGRNASGVKLINTADKVMYVNSCPKEEEPENLETSSAQNLFE



>gb|NC_000915.1|+|752512-754995|Helicobacter pylori gyrA conferring resistance to fluoroquinolones [Helicobacter pylori]
ATGCAAGATAATTCAGTCAATGAAACAAAAAATATTGTAGAAGTGGGGATTGATTCTTCTATTGAAGAGAGCTATTTAGCTTATTCCATG
AGCGTGATCATAGGGCGCGCTTTACCGGACGCTAGAGATGGCTTAAAGCCCGTGCATAGGCGTATTTTGTATGCGATGCATGAATTAGGC
CTTACTTCAAAAGTCGCTTACAAAAAAAGCGCTAGGATCGTGGGTGATGTGATTGGTAAATACCACCCCCATGGCGATAATGCGGTTTAT
GATGCGCTAGTGAGAATGGCGCAAGATTTTTCCATGCGTTTGGAATTAGTGGATGGGCAGGGCAACTTTGGCTCTATTGATGGCGATAAC
GCCGCAGCGATGCGTTACACTGAAGCCAGAATGACTAAGGCGAGTGAAGAAATTTTAAGGGATATTGATAAAGACACCATTGATTTTGTG
CCTAATTATGACGATACCTTAAAAGAGCCAGATATTTTACCAAGCCGTCTGCCTAACCTTTTAGTCAATGGGGCTAATGGGATCGCTGTG
GGGATGGCGACTTCTATCCCCCCTCACAGGATGGATGAAATCATAGACGCTTTAGTGCATGTCTTAGAAAACCCTAACGCTGGATTAGAT
GAAATCTTAGAATTTGTCAAAGGGCCTGATTTTCCCACTGGTGGGATCATTTATGGCAAGGCGGGTATTATTGAAGCCTATAAAACGGGG
CGAGGACGCGTGAAAGTGCGGGCCAAAGTGCATGTGGAAAAAACAAAAAATAAAGAAATCATCGTTTTAGATGAAATGCCTTTTCAAACC
AATAAAGCCAAATTAGTGGAACAAATCAGCGATTTAGCGCGAGAAAAGCAAATTGAAGGCATTAGTGAAGTGCGCGATGAGAGCGATAGA
GAGGGCATTAGAGTGGTGATTGAATTAAAAAGAGACGCGATGAGTGAAATTGTCTTAAACCACCTCTACAAACTCACCACTATGGAAACC
ACTTTTAGCATCATTTTACTCGCTATTTACAATAAAGAGCCTAAGATTTTCACGCTTTTAGAGTTGTTGCACCTTTTCTTAAACCACAGA
AAAACCATTATTATAAGACGCACGATTTTTGAATTAGAAAAGGCTAAGGCCAGAGCGCATATTTTAGAGGGCTATTTGATCGCACTAGAC
AATATTGATGAAATCGTGCGACTCATTAAAACAAGCCAAAGCCCAGAAGCGGCTAAAAACGCCTTAATGGAGCGTTTCACTTTGAGCGAG
ATTCAAAGCAAGGCCATTTTAGAAATGCGTTTGCAACGCTTAACAGGCCTTGAAAGGGATAAGATCAAAGAAGAATACCAAAACTTGTTG
GAGCTTATTGATGATCTCAATGGCATTTTAAAGAGCGAAGATCGCTTGAATGGAGTCGTCAAAACAGAGCTTTTAGAAGTCAAAGAGCAA
TTTTCTTCTCCAAGGCGCACTGAAATTCAAGAATCTTATGAAAATATTGACATAGAAGATTTGATCGCTAATGAGCCTATGGTAGTGAGC
ATGAGTTATAAAGGCTATGTGAAAAGAGTGGATTTAAAAGCTTATGAAAAGCAAAATCGTGGTGGTAAAGGCAAGCTTTCAGGCAGCACT
TATGAAGACGATTTCATTGAAAACTTTTTTGTGGCTAACACGCATGATATTTTGCTCTTTATCACCAATAAGGGGCAATTGTATCATTTG
AAAGTCTATAAAATCCCAGAAGCGAGCCGGATCGCTATGGGTAAAGCCATTGTAAATTTAATCTCGCTCGCTCCGGATGAAAAGATCATG
GCGACTCTAAGCACCAAAGACTTTAGCGATGAACGCTCTTTGGCCTTCTTCACGAAAAATGGCGTGGTGAAGCGCACCAATTTGAGCGAA
TTTGAAAGCAACAGGAGTTGTGGTATCAGAGCGATTGTTTTAGATGAAGGCGATGAATTAGTGAGCGCAAAAGTTGTGGATAAAAACGCT
AAGCATTTGCTCATCGCATCGCATTTGGGCATTTTCATTAAATTCCCTTTAGAAGAGGTGCGCGAGATCGGAAGAACTACTCGTGGGGTT
ATAGGCATCAAGCTGAATGAAAACGATTTTGTTGTCGGTGCGGTCGTTATTAGCGATGATGGCAACAAGCTTTTGAGCGTGAGTGAAAAC
GGGCTTGGCAAGCAAACTTTAGCCGAAGCGTATAGAGGGCAATCTCGTGGAGGTAAGGGGGTCATTGGCATGAAGCTCACTCAAAAAACC
GGCAATCTAGTGGGCGTTATCAGCGTGGATGATGAAAATTTGGATTTGATGATCCTTACTGCAAGCGCAAAAATGATCAGAGTTTCTATT
AAAGATATTAGAGAAACCGGAAGAAACGCTAGTGGGGTAAAGCTCATAAACACCGCCGATAAAGTCATGTATGTCAATTCTTGCCCTAAA
GAAGAAGAGCCAGAAAATTTAGAAACCTCTTCGGCACAAAATTTGTTTGAGTGA